Details for New Drug Application (NDA): 208718
✉ Email this page to a colleague
NDA 208718 describes IRINOTECAN HYDROCHLORIDE, which is a drug marketed by Accord Hlthcare, Actavis Totowa, Chartwell Rx, Cipla Ltd, Emcure Pharms Ltd, Epic Pharma Llc, Eugia Pharma, Fresenius Kabi Usa, Gland, Hengrui Pharma, Hikma, Hikma Farmaceutica, Hisun Pharm Hangzhou, Hospira, Ingenus Pharms Llc, Intas Pharms Usa, Pharmobedient, Pliva Lachema, Qilu Pharm Hainan, Sandoz, Shilpa, Sun Pharma Global, and Teva Pharms Usa, and is included in twenty-six NDAs. It is available from thirteen suppliers. Additional details are available on the IRINOTECAN HYDROCHLORIDE profile page.
The generic ingredient in IRINOTECAN HYDROCHLORIDE is irinotecan hydrochloride. There is one drug master file entry for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the irinotecan hydrochloride profile page.
The generic ingredient in IRINOTECAN HYDROCHLORIDE is irinotecan hydrochloride. There is one drug master file entry for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the irinotecan hydrochloride profile page.
Summary for 208718
| Tradename: | IRINOTECAN HYDROCHLORIDE |
| Applicant: | Shilpa |
| Ingredient: | irinotecan hydrochloride |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | 40MG/2ML (20MG/ML) | ||||
| Approval Date: | Dec 28, 2018 | TE: | AP | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | 100MG/5ML (20MG/ML) | ||||
| Approval Date: | Dec 28, 2018 | TE: | AP | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | 300MG/15ML (20MG/ML) | ||||
| Approval Date: | Aug 16, 2019 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
